The US Food and Drug Administration granted CSPC Pharmaceutical (HKG:1093) fast track designation for its CPO301 treatment for lung cancer patients, according to a Tuesday filing with the Hong Kong Exchange.
The drug is indicated for patients with recurrent or metastatic squamous non-small cell lung cancer with an overexpression of epidermal growth factor receptor despite platinum-based chemotherapy, among other therapies, the filing said.
Price (HKD): $7.04, Change: $-0.080, Percent Change: -1.12%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.